

31 Mar 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 29 March 2024, including: [Merck & Co., Inc.](#) progresses cardiovascular strategy; [Novo Nordisk A/S](#) purchase builds heart failure presence; CRL setbacks for [Regeneron Pharmaceuticals, Inc.](#); ITF faces challenging Duchenne field; and [AbbVie Inc.](#) needs to freshen up.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy](#)" - Scrip, 26 Mar, 2024.)

(Also see "[Novo Pumps Up Heart Failure Prospects With Cardior Purchase](#)" - Scrip, 25 Mar, 2024.)

(Also see "[Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval](#)" - Scrip, 25 Mar, 2024.)

(Also see "[ITF Has A Fight On Its Hands In Duchenne](#)" - Scrip, 25 Mar, 2024.)

(Also see "[AbbVie Needs To Freshen Up](#)" - Scrip, 22 Mar, 2024.)

[Click here to explore this interactive content online](#) ✨